Independent Articles Psychedelic Treatment with Psilocybin: Addressing Medical Malpractice Risk and Physicians’ Concerns Katherine Cheung1, Maxwell Brodie2, Sue-Ling Chang3, Pierre Deschamps4, Jean-Sébastien Fallu5, Houman Farzin6,7 , Johanne Hébert8,9, Jean-François Stephan10, Michel Dorval11,12 and Yann Joly2 for the P3A Study Group 1National Institutes of Health, Bethesda, United States; 2McGill University Centre of Genomics and Policy, Montreal, Canada; 3Axe Oncologie, Centre de recherche du CHU de Québec-Université Laval, Canada; 4Independant author, Canada; 5Universite de Montreal, Montreal, Canada; 6Jewish General Hospital, Montreal, Canada; 7McGill University, Montreal, Canada; 8Department of Nursing Sciences, Universite du Quebec a Rimouski, Rimouski, Canada; 9Centre de recherche du CISSS de Chaudière-Appalaches, Canada; 10Institut universitaire de santé mentale de Montréal, Canada; 11Universite Laval Faculte de Pharmacie, Québec City, Canada and 12Axe Oncologie, Centre de recherche du CHU de Québec, Canada Abstract Psychedelic treatment with psilocybin is receiving increased attention following clinical trials showing it may help treat end-of-life anxiety, depression, and several other conditions. Despite this, physicians may be reluctant to prescribe psilocybin and carry out psilocybin treatment because of the stigma surrounding psychedelics and the potential for medical malpractice liability. This paper explores whether psilocybin treatment gives rise to a risk of medical malpractice liability for physicians. Following an overview of psilocybin treatment and its regulatory regime in Canada, exploratory vignettes are used to highlight the relevance and limits of malpractice claims. This paper argues that the lack of established medical standards, standardized training, and credentialing contribute to liability risks surrounding psilocybin treatment. More clinical trials, meta-studies of research analyses, and knowledge sharing will help to develop trainin…
New open-access on FirstView: "Psychedelic Treatment with Psilocybin: Addressing Medical Malpractice Risk and Physicians’ Concerns" by members of the P3A Study Group including @katherinecheung.bsky.social & @jsfallu.bsky.social.
#psilocybin #PsychedelicTreatment
www.cambridge.org/core/journal...
